BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32832624)

  • 1. RACK7 recognizes H3.3G34R mutation to suppress expression of MHC class II complex components and their delivery pathway in pediatric glioblastoma.
    Jiao F; Li Z; He C; Xu W; Yang G; Liu T; Shen H; Cai J; Anastas JN; Mao Y; Yu Y; Lan F; Shi YG; Jones C; Xu Y; Baker SJ; Shi Y; Guo R
    Sci Adv; 2020 Jul; 6(29):eaba2113. PubMed ID: 32832624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas.
    Sweha SR; Chung C; Natarajan SK; Panwalkar P; Pun M; Ghali A; Bayliss J; Pratt D; Shankar A; Ravikumar V; Rao A; Cieslik M; Wilder-Romans K; Scott AJ; Wahl DR; Jessa S; Kleinman CL; Jabado N; Mackay A; Jones C; Martinez D; Santi M; Judkins AR; Yadav VN; Qin T; Phoenix TN; Koschmann CJ; Baker SJ; Chinnaiyan AM; Venneti S
    Sci Transl Med; 2021 Oct; 13(615):eabf7860. PubMed ID: 34644147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting the impact of regional identity and the oncogenic role of human-specific NOTCH2NL in an hESC model of H3.3G34R-mutant glioma.
    Funato K; Smith RC; Saito Y; Tabar V
    Cell Stem Cell; 2021 May; 28(5):894-905.e7. PubMed ID: 33631117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation.
    Zika E; Greer SF; Zhu XS; Ting JP
    Mol Cell Biol; 2003 May; 23(9):3091-102. PubMed ID: 12697811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of
    Abdallah AS; Cardona HJ; Gadd SL; Brat DJ; Powla PP; Alruwalli WS; Shen C; Picketts DJ; Li XN; Becher OJ
    Neurooncol Adv; 2023; 5(1):vdad003. PubMed ID: 36845293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies.
    Voon HPJ; Hii L; Garvie A; Udugama M; Krug B; Russo C; Chüeh AC; Daly RJ; Morey A; Bell TDM; Turner SJ; Rosenbluh J; Daniel P; Firestein R; Mann JR; Collas P; Jabado N; Wong LH
    Genome Biol; 2023 Dec; 24(1):284. PubMed ID: 38066546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells.
    Kitamura N; Yokoyama H; Yashiro T; Nakano N; Nishiyama M; Kanada S; Fukai T; Hara M; Ikeda S; Ogawa H; Okumura K; Nishiyama C
    J Allergy Clin Immunol; 2012 Mar; 129(3):814-824.e6. PubMed ID: 22112519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?
    Chan KM; Han J; Fang D; Gan H; Zhang Z
    Cell Cycle; 2013 Aug; 12(16):2546-52. PubMed ID: 23907119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelogenin Downregulates Interferon Gamma-Induced Major Histocompatibility Complex Class II Expression Through Suppression of Euchromatin Formation in the Class II Transactivator Promoter IV Region in Macrophages.
    Yotsumoto K; Sanui T; Tanaka U; Yamato H; Alshargabi R; Shinjo T; Nakao Y; Watanabe Y; Hayashi C; Taketomi T; Fukuda T; Nishimura F
    Front Immunol; 2020; 11():709. PubMed ID: 32373130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter.
    Choi YE; Yu HN; Yoon CH; Bae YS
    Eur J Immunol; 2009 Mar; 39(3):858-68. PubMed ID: 19224634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.
    Hake SB; Masternak K; Kammerbauer C; Janzen C; Reith W; Steimle V
    Mol Cell Biol; 2000 Oct; 20(20):7716-25. PubMed ID: 11003667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR2 Promotes Glioma Immune Evasion by Downregulating MHC Class II Molecules in Microglia.
    Qian J; Luo F; Yang J; Liu J; Liu R; Wang L; Wang C; Deng Y; Lu Z; Wang Y; Lu M; Wang JY; Chu Y
    Cancer Immunol Res; 2018 Oct; 6(10):1220-1233. PubMed ID: 30131377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 17beta-Estradiol inhibits class II major histocompatibility complex (MHC) expression: influence on histone modifications and cbp recruitment to the class II MHC promoter.
    Adamski J; Ma Z; Nozell S; Benveniste EN
    Mol Endocrinol; 2004 Aug; 18(8):1963-74. PubMed ID: 15143155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mutations in histone H3.3 and chromatin remodeling genes drive pediatric and young adult glioblastomas].
    Khuong-Quang DA; Gerges N; Jabado N
    Med Sci (Paris); 2012 Oct; 28(10):809-12. PubMed ID: 23067407
    [No Abstract]   [Full Text] [Related]  

  • 15. FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.
    Kasuga Y; Ouda R; Watanabe M; Sun X; Kimura M; Hatakeyama S; Kobayashi KS
    Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2218955120. PubMed ID: 37279268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZMYND8 Reads the Dual Histone Mark H3K4me1-H3K14ac to Antagonize the Expression of Metastasis-Linked Genes.
    Li N; Li Y; Lv J; Zheng X; Wen H; Shen H; Zhu G; Chen TY; Dhar SS; Kan PY; Wang Z; Shiekhattar R; Shi X; Lan F; Chen K; Li W; Li H; Lee MG
    Mol Cell; 2016 Aug; 63(3):470-84. PubMed ID: 27477906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma.
    Voon HPJ; Udugama M; Lin W; Hii L; Law RHP; Steer DL; Das PP; Mann JR; Wong LH
    Nat Commun; 2018 Aug; 9(1):3142. PubMed ID: 30087349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
    Schwartzentruber J; Korshunov A; Liu XY; Jones DT; Pfaff E; Jacob K; Sturm D; Fontebasso AM; Quang DA; Tönjes M; Hovestadt V; Albrecht S; Kool M; Nantel A; Konermann C; Lindroth A; Jäger N; Rausch T; Ryzhova M; Korbel JO; Hielscher T; Hauser P; Garami M; Klekner A; Bognar L; Ebinger M; Schuhmann MU; Scheurlen W; Pekrun A; Frühwald MC; Roggendorf W; Kramm C; Dürken M; Atkinson J; Lepage P; Montpetit A; Zakrzewska M; Zakrzewski K; Liberski PP; Dong Z; Siegel P; Kulozik AE; Zapatka M; Guha A; Malkin D; Felsberg J; Reifenberger G; von Deimling A; Ichimura K; Collins VP; Witt H; Milde T; Witt O; Zhang C; Castelo-Branco P; Lichter P; Faury D; Tabori U; Plass C; Majewski J; Pfister SM; Jabado N
    Nature; 2012 Jan; 482(7384):226-31. PubMed ID: 22286061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
    Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
    J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The arginine methyltransferase PRMT5 regulates CIITA-dependent MHC II transcription.
    Fan Z; Kong X; Xia J; Wu X; Li H; Xu H; Fang M; Xu Y
    Biochim Biophys Acta; 2016 May; 1859(5):687-96. PubMed ID: 26972221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.